Peregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed Glioblastoma
September 07, 2017 08:10 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing...
TESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042
April 27, 2017 08:15 ET
|
TESARO, Inc.
TSR-042 is the first TESARO immuno-oncology candidate to enter a registration programOngoing clinical trial expanded to enroll patients with endometrial cancerPatient-centric administration...
Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2017 and Recent Developments
December 12, 2016 16:05 ET
|
Peregrine Pharmaceuticals Inc.
-- Avid Posts Record Revenue of $23.4 Million During Second Quarter FY 2017 with Contracted Backlog of Future Business Currently at $73 Million -- -- Beta-2 Glycoprotein-1 (β2GP1) Identified as a...
New Study Demonstrates Anti-Tumor Advantages for Combination Treatment Featuring Peregrine Pharmaceuticals’ PS-Targeting Antibodies in a Preclinical Melanoma Model
November 14, 2016 08:05 ET
|
Peregrine Pharmaceuticals Inc.
-- Promising Results of MSK Study Evaluating Combinations of PS-Targeting Treatment, Anti-PD-1 and Radiation in Mouse B16 Melanoma Model Presented at SITC 2016 -- -- New Data from Second Study...
Preclinical Research Demonstrates Peregrine Pharmaceuticals’ PS-Targeting Antibodies Enhance the Anti-Tumor Activity of PD-L1 Checkpoint Inhibitors in Model of Triple Negative Breast Cancer (TNBC)
October 24, 2016 08:05 ET
|
Peregrine Pharmaceuticals Inc.
-- Combination of PS-Targeting Antibody and Anti-PD-L1 Therapy, With or Without Chemotherapy, Led to Greater Anti-Tumor Activity Than Single Agent Treatment or Dual Combinations With Chemotherapy -- ...
TESARO Announces Submission of Investigational New Drug Application for Anti-TIM-3 Antibody TSR-022 to the U.S. FDA
April 25, 2016 08:05 ET
|
TESARO, Inc.
WALTHAM, Mass., April 25, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the submission of an Investigational New Drug (IND)...
Peregrine Pharmaceuticals Reports Financial Results for Third Quarter of Fiscal Year 2016 and Recent Developments
March 09, 2016 08:00 ET
|
Peregrine Pharmaceuticals Inc.
--Company Focused on Advancing Its Bavituximab Immuno-Oncology Program Through Its Pharmaceutical, Academic and Clinical Collaborations-- --Full Fiscal Year 2016 Revenue From Biomanufacturing...
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
March 07, 2016 16:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., March 07, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend...
Peregrine Pharmaceuticals to Present at Two Upcoming Cancer Immunotherapy Conferences
January 20, 2016 08:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Jan. 20, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the...
Peregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program in Lung, Breast and Other Cancers
January 11, 2016 08:05 ET
|
Peregrine Pharmaceuticals Inc.
-- Phase II Study in NSCLC in Collaboration with AstraZeneca Evaluating Bavituximab Plus Durvalumab to Expand Lung Cancer Program in Q1 2016 -- -- Phase II/III Study in HER2-Negative Metastatic...